Stocktoria
Eurofins Scientific SE ERF.PA
FR · Euronext Paris · XPAR · stock · Healthcare · website
Eurofins Scientific SE financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €7.3B | €7.0B | €6.5B | €6.7B |
| Gross profit | €5.0B | €4.7B | €4.4B | €4.5B |
| Operating income | €818.3M | €726.2M | €546.8M | €783.2M |
| Interest expense | €157.1M | €150.8M | €129.4M | €105.6M |
| Income tax | €181.1M | €149.1M | €115.5M | €174.2M |
| Net income | €474.8M | €406.4M | €310.2M | €610.2M |
| EPS (diluted) | €2.55 | €2.09 | €1.57 | €3.07 |
| Operating cash flow | €1.4B | €1.3B | €1.0B | €1.1B |
| Free cash flow | €564.1M | €790.5M | €467.8M | €476.1M |
| Cash & equivalents | €791.2M | €613.9M | €1.2B | €486.6M |
| Inventory | €139.3M | €141.9M | €139.0M | €145.6M |
| Goodwill | €4.7B | €4.8B | €4.6B | €4.5B |
| Total assets | €11.0B | €10.9B | €10.9B | €10.1B |
| Total debt | €4.4B | €3.6B | €3.9B | €3.3B |
| Total liabilities | €6.4B | €5.5B | €5.8B | €5.2B |
| Shareholders' equity | €4.5B | €5.3B | €5.1B | €4.8B |
| Share buybacks | €541.3M | €271.9M | €55.8M | €15.8M |
Growth · year-over-year · Revenue CAGR 2.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +5.0% | +6.7% | -2.9% | — |
| Net income growth | +16.8% | +31.0% | -49.2% | — |
| EPS growth | +22.0% | +33.1% | -48.9% | — |
| Free cash flow growth | -28.6% | +69.0% | -1.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · FR · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.